Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| AVXL | Anavex Life Sciences | $3.26 | -$2.43 | -42.71% | 13.8M | $488.7M | $2.86$14.44 |
| TSSI | Tss | $8.87 | -$6.38 | -41.84% | 4M | $432.6M | $5.63$31.94 |
| GAUZ | Gauzy | $2.52 | -$1.50 | -37.32% | 461.3K | $75.3M | $1.98$13.00 |
| GWH | ESS Tech | $3.04 | -$1.22 | -28.59% | 666.7K | $83.4M | $0.76$13.87 |
| STUB | StubHub | $14.35 | -$4.47 | -23.77% | 7.8M | $6.9B | $12.91$27.89 |
| ONEG | OneConstruction Group | $8.26 | -$2.00 | -19.49% | 1M | $164.2M | $1.48$13.50 |
| SGBX | Safe & Green | $2.56 | -$0.60 | -18.99% | 1.6M | $1.5M | $1.81$122.88 |
| SOC | Sable Offshore | $4.83 | -$1.07 | -18.08% | 3.9M | $586.1M | $4.58$35.00 |
| AIRO | Airo Group | $10.82 | -$1.93 | -15.17% | 846.3K | $403.2M | $9.90$39.07 |
| CWD | CaliberCos | $2.38 | -$0.39 | -14.11% | 101.6K | $13.8M | $1.63$48.00 |
Related Articles
Featured Article
Wall Street Thinks This Small-Cap Stock Can Quadruple in Value
David Jagielski|Mar 15, 2023
The company generates no revenue, but it may be worth taking a chance on as it possesses lots of upside.
Is Anavex Life Sciences Stock a Buy Now?
David Jagielski|Feb 23, 2023
A short squeeze could be a possibility if the company can prove that bearish investors are wrong about its business.
This Short-Squeeze Candidate Could Actually Pan Out in the Long Run
George Budwell|Feb 9, 2023
Short-sellers have piled into this clinical-stage biopharma stock.
Anavex Life Sciences Stock Could 5x Before 2025 -- Here's Why
Alex Carchidi|Dec 17, 2022
The biotech will first need to assuage the concerns of experts by elaborating on its latest clinical trial data.
Is Anavex Life Sciences a Buy?
Alex Carchidi|Dec 13, 2022
It still needs to prove that its lead program is as effective as it claims for treating Alzheimer's.
Is Anavex Life Sciences a Smart Stock to Buy Now?
Cory Renauer|Dec 3, 2022
The company's Alzheimer's disease drug just succeeded in a clinical trial. Or did it?
2 Biotech Stocks Set to Go Supernova Soon
George Budwell|Oct 18, 2021
Anavex Life Sciences and Affimed both sport unique drug development platforms that could be worth billions.
3 Biotech Stocks That Have Already Doubled This Year
Cory Renauer|Feb 20, 2020
Can these soaring biotech stocks keep climbing?
Forget Anavex Life Sciences Corp.: These 2 Biotech Stocks Are Better Buys
Cory Renauer|Feb 1, 2017
The tiny biotech's only clinical-stage candidate is a long way from the goal line, making these two biotech stocks far better picks.
Anavex Life Sciences Corp. in 3 Charts
Keith Speights|Dec 6, 2016
These charts show where things stand -- and where they could be headed -- for Alzheimer's disease drug developer Anavex Life Sciences.
